All In Biotech

Drug Trial Radar · NCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation

Last checked: Nov 19, 2026Latest source record: Jan 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,731 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,731

Actual

Start

Jun 1, 2011

Primary completion

Mar 18, 2013

Study completion Mar 2, 2015

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline. Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Interventions

  • liraglutideDrug

    Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).

  • placeboDrug

    Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).

  • liraglutideDrug

    Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.

  • placeboDrug

    Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Fasting Body WeightTime frame: Week 0, Week 56
  2. Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.Time frame: At Week 56
  3. Proportion of Subjects Losing More Than 10% of Baseline Fasting Body WeightTime frame: At 56 weeks
  4. Proportion of Subjects With Onset of Type 2 DiabetesTime frame: At 160 weeks

Locations

226 sites in 29 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Phoenix, Arizona

  • Novo Nordisk Investigational Site

    Anaheim, California

  • Novo Nordisk Investigational Site

    Concord, California

  • Novo Nordisk Investigational Site

    Huntington Beach, California

  • Novo Nordisk Investigational Site

    La Jolla, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    Santa Monica, California

  • Novo Nordisk Investigational Site

    Aurora, Colorado

  • Novo Nordisk Investigational Site

    Colorado Springs, Colorado

  • Novo Nordisk Investigational Site

    Golden, Colorado

  • Novo Nordisk Investigational Site

    New London, Connecticut

  • Novo Nordisk Investigational Site

    Waterbury, Connecticut

  • Novo Nordisk Investigational Site

    Washington D.C., District of Columbia

  • Novo Nordisk Investigational Site

    Boynton Beach, Florida

  • Novo Nordisk Investigational Site

    Bradenton, Florida

  • Novo Nordisk Investigational Site

    Crystal River, Florida

  • Novo Nordisk Investigational Site

    Daytona Beach, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Ocala, Florida

  • Novo Nordisk Investigational Site

    Ponte Vedra, Florida

  • Novo Nordisk Investigational Site

    South Miami, Florida

  • Novo Nordisk Investigational Site

    Athens, Georgia

  • Novo Nordisk Investigational Site

    Dunwoody, Georgia

  • Novo Nordisk Investigational Site

    Sandy Springs, Georgia

  • Novo Nordisk Investigational Site

    Suwanee, Georgia

  • Novo Nordisk Investigational Site

    Aurora, Illinois

  • Novo Nordisk Investigational Site

    Topeka, Kansas

  • Novo Nordisk Investigational Site

    Baton Rouge, Louisiana

  • Novo Nordisk Investigational Site

    Baltimore, Maryland

  • Novo Nordisk Investigational Site

    Elkridge, Maryland

  • Novo Nordisk Investigational Site

    North Dartmouth, Massachusetts

  • Novo Nordisk Investigational Site

    City of Saint Peters, Missouri

  • Novo Nordisk Investigational Site

    Kansas City, Missouri

  • Novo Nordisk Investigational Site

    St Louis, Missouri

  • Novo Nordisk Investigational Site

    St Louis, Missouri

  • Novo Nordisk Investigational Site

    New York, New York

  • Novo Nordisk Investigational Site

    Rochester, New York

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.